From USFDA
Alembic Pharmaceuticals announced that the Company has received approval from the US Food & Drug Administration for its Abbreviated New Drug Application for Fenofibric Acid Delayed-Release Capsules, 45 mg and 135 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product Trilipix Delayed Release Capsules, 45 mg and 135 mg of Abbvie Inc.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
